Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 2/20 | 0.41 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | SERPINA3 | P01011 | 1/20 | 0.34 |
| ▸ | AHCY | P23526 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20820158 | 1.00 | HINT1 (0.41) | HINT1BTN3A1CYP3A4CYP2C9HSP90B1 | |
| SCHEMBL21136926 | 0.94 | HINT1 (0.42) | HINT1BTN3A1CYP3A4CYP2C9HSP90B1 | |
| SCHEMBL21136218 | 0.93 | HINT1 (0.40) | HINT1BTN3A1CYP3A4CYP2C9HSP90B1 | |
| SCHEMBL20820179 | 0.91 | HINT1 (0.39) | HINT1BTN3A1CYP3A4CYP2C9HSP90B1 | |
| SCHEMBL20820211 | 0.91 | HINT1 (0.39) | HINT1BTN3A1CYP3A4CYP2C9HSP90B1 | |
| SCHEMBL20820156 | 0.90 | HINT1 (0.37) | HINT1BTN3A1CYP3A4CYP2C9HSP90B1 | |
| SCHEMBL20820206 | 0.90 | HINT1 (0.37) | HINT1BTN3A1CYP3A4CYP2C9HSP90B1 | |
| SCHEMBL20402389 | 0.88 | SERPINA3 (0.41) | HINT1BTN3A1CYP3A4CYP2C9NT5E | |
| SCHEMBL18458037 | 0.87 | CYP3A4 (0.39) | HINT1BTN3A1CYP3A4CYP2C9NT5E | |
| SCHEMBL20402084 | 0.87 | CYP3A4 (0.39) | HINT1BTN3A1CYP3A4CYP2C9NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10231986-B2 | Amino acid phosphoramidate pronucleotides of 2′-cyano, azido and amino nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10231986-B2 | Amino acid phosphoramidate pronucleotides of 2′-cyano, azido and amino nucleosides for the treatment of HCV | PNP, RNGTT, NSUN2 | HINT1 396/4885BTN3A1 2884/4885CYP3A4 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.